可降低活动性狼疮几率和预防复发的羟氯喹血药浓度参考范围
研究探讨羟氯喹血药浓度与狼疮活动及复发的关系。158次基线访视中19%有活动性狼疮,血药浓度750至1200 ng/mL者活动性狼疮几率降低71%(调整比值比0.29,95%置信区间0.08-0.96);纵向随访42例中17%复发,维持该浓度范围使复发几率降低26%。
要点
- 羟氯喹血药浓度750至1200 ng/mL与活动性狼疮几率降低71%相关。
- 维持羟氯喹血药浓度在750至1200 ng/mL使复发几率降低26%。
- 上述参考范围可能指导临床个体化调整羟氯喹剂量。
核心结论
- 羟氯喹血药浓度750至1200 ng/mL的有效参考范围与活动性狼疮几率降低71%相关,维持该范围使复发几率降低26%。
研究设计与样本
- 在基线访视和常规随访访视时测量全血羟氯喹浓度和系统性红斑狼疮疾病活动指数(SLEDAI)。
- 基线活动性狼疮定义为SLEDAI≥6,受试者内复发定义为随后SLEDAI增加3分且伴有临床症状需要改变治疗。
- 采用混合回归分析检查基线和6至12个月常规随访访视时活动性狼疮与羟氯喹血药浓度、复发与羟氯喹浓度之间的关联。
主要发现
- 在158次基线患者访视中,19%有活动性狼疮。
- 血药浓度在750至1200 ng/mL范围内的患者活动性狼疮几率降低71%(调整比值比0.29,95%置信区间0.08-0.96)。
- 在大流行期间采用方便抽样策略纵向随访42例患者,其中17%在随访访视期间复发。
- 维持羟氯喹浓度在750至1200 ng/mL范围内使九个月中位随访期间复发几率降低26%。
关键数值与推荐
- 活动性狼疮定义为SLEDAI≥6。
- 受试者内复发定义为随后SLEDAI增加3分且伴有临床症状需要改变治疗。
- 有效参考范围为羟氯喹血药浓度750至1200 ng/mL。
临床怎么用
- 作者认为这些发现可指导临床医生个体化调整羟氯喹剂量,以维持羟氯喹浓度在该范围内最大化疗效。
局限性
- 采用方便抽样策略在大流行期间进行纵向随访。
- 纵向随访样本量为42例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recent data show that lower hydroxychloroquine (HCQ) doses are associated with a two- to six-fold higher risk of lupus flares. Thus, establishing an effective reference range of HCQ blood levels with upper and lower bounds for efficacy may support individualizing HCQ dosing to prevent flares. METHODS: HCQ levels in whole blood and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were measured during the baseline visit and again during a standard of care routine follow-up visit. Active cross-sectional lupus at baseline was defined as SLEDAI ≥6; a within subject flare was defined as a subsequent three-point increase in SLEDAI with clinical symptoms requiring therapy change. We examined associations between active lupus and HCQ blood levels at baseline and flares and HCQ levels during 6 to 12-month routine lupus follow-up visits using mixed regression analysis. RESULTS: Among 158 baseline patient visits, 19% had active lupus. Odds of active lupus were 71% lower in patients with levels within a 750 to 1,200 ng/mL range (adjusted odds ratio 0.29, 95% confidence interval 0.08-0.96). Using convenience sampling strategy during a pandemic, we longitudinally followed 42 patients. Among those patients, 17% flared during their follow-up visit. Maintaining HCQ levels within 750 to 1,200 ng/mL reduced the odds of a flare by 26% over a nine-month median follow-up. CONCLUSION: An effective reference range of HCQ blood levels, 750 to 1,200 ng/mL, was associated with 71% lower odds of active lupus, and maintaining levels within this range reduced odds of flares by 26%. These findings could guide clinicians to individualize HCQ doses to maintain HCQ levels within this range to maximize efficacy.
引用
- Garg S, Chewning B, Hutson P, et al. Reference Range of Hydroxychloroquine Blood Levels That Can Reduce Odds of Active Lupus and Prevent Flares. Arthritis Care Res (Hoboken). 2023. PMID: 37667434. doi:10.1002/acr.25228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。